1 – 10 of 21
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
The hematopoietic tumor suppressor interferon regulatory factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms' tumor gene 1 (WT1) protein.
(
- Contribution to journal › Article
- 2014
-
Mark
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
2014) In Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis 38(12). p.1381-1391(
- Contribution to journal › Scientific review
-
Mark
Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays.
(
- Contribution to journal › Article
- 2013
-
Mark
Leukemia associated mutant Wilms' tumor gene 1 protein promotes expansion of human hematopoietic progenitor cells.
2013) In Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis 37(10). p.1341-1349(
- Contribution to journal › Article
- 2012
-
Mark
Additional aberrations of the ETV6 and RUNX1 genes have no prognostic impact in 229 t(12;21)(p13;q22)-positive B-cell precursor acute lymphoblastic leukaemias treated according to the NOPHO-ALL-2000 protocol
(
- Contribution to journal › Letter
-
Mark
Nucleolar proteins with altered expression in leukemic cell lines.
(
- Contribution to journal › Article
- 2011
-
Mark
TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia
(
- Contribution to journal › Article
-
Mark
t(9;11)(p22;p15) [NUP98/PSIP1] is a poor prognostic marker associated with de novo acute myeloid leukaemia expressing both mature and immature surface antigens.
(
- Contribution to journal › Letter
- 2010
-
Mark
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia
(
- Contribution to journal › Article
-
Mark
Exploring novel therapeutic options in T-LGL, including epigenetic modulation: A case report.
(
- Contribution to journal › Letter